Related Experiment Video

Updated: Mar 21, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Blockade of RAS-Binding Domain Interactions Inhibits RAS Signaling

    Cancer Discovery
    |May 7, 2016
    PubMed

    Insights

    Rigosertib mimics RAS proteins by binding to effector proteins. This action disrupts signaling pathways crucial for cancer cell growth and survival.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Drug Discovery

    Background:

    • RAS proteins are key regulators of cellular signaling pathways.
    • Dysregulation of RAS signaling is implicated in numerous cancers.
    • Targeting RAS effectors presents a therapeutic strategy for cancer treatment.

    Discussion:

    • Rigosertib functions as a RAS mimetic, directly interacting with the RAS-binding domain.
    • This interaction inhibits the activity of multiple RAS effector proteins.
    • The mechanism involves competitive binding, preventing downstream signaling.

    Key Insights:

    • Rigosertib's ability to bind to the RAS-binding domain of multiple effectors is a novel mechanism of action.
    • This broad inhibitory potential suggests efficacy across various RAS-driven cancers.
    • Understanding this interaction is critical for Rigosertib's clinical development.

    Outlook:

    • Further research into Rigosertib's precise binding kinetics and downstream effects is warranted.
    • Clinical trials will evaluate Rigosertib's efficacy and safety in patients with RAS-mutated cancers.
    • This therapeutic approach may offer new hope for difficult-to-treat malignancies.

    More Related Videos

    Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

    Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

    Published on: March 1, 2024

    1.9K
    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

    Published on: October 5, 2020

    3.4K

    Related Concept Videos

    The Ras Gene02:38

    The Ras Gene

    The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
    Ras is a...
    7.5K
    The JAK-STAT Signaling Pathway01:20

    The JAK-STAT Signaling Pathway

    Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
    13.7K
    Small GTPases - Ras and Rho01:24

    Small GTPases - Ras and Rho

    Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
    Three regulatory proteins control their activity:
    5.7K
    MAPK Signaling Cascades01:07

    MAPK Signaling Cascades

    Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
    9.1K
    Interactions Between Signaling Pathways01:19

    Interactions Between Signaling Pathways

    Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
    Convergence and divergence, and cross-talk between signaling pathways
    Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
    7.8K
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    6.2K